The effect of mineralocorticoid receptor antagonists on recruitment and function of endothelial progenitor cells in patients with congestive heart failure

Israel Medical Association Journal

Volumn 20, Issue 4, 2018, Pages 233-238

  Levi, Amos ^a,b   Leshem Lev, Dorit ^a,b   Weissler Snir, Adaya ^a,b   Hasin, Tal ^a,b   Mats, Israel ^a,b   Murninkas, Daniel ^a,b   Kornowski, Ran ^a,b   Lev, Eli I ^a,b   Ben Gal, Tuvia ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Circulating endothelial progenitor cells (EPCs); Congestive heart failure (CHF); Mineralocorticoid receptor (MR) antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD133 ANTIGEN; CD34 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; VASCULOTROPIN RECEPTOR 2; PROM1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CELL CULTURE; CELL FUNCTION; CELL VIABILITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIURETIC THERAPY; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MICROSCOPY; MONONUCLEAR CELL; MTT ASSAY; RANDOMIZED CONTROLLED TRIAL; CELL SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEART FAILURE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AC133 ANTIGEN; AGED; ANTIGENS, CD34; CELL SURVIVAL; COHORT STUDIES; ENDOTHELIAL PROGENITOR CELLS; EPLERENONE; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; SPIRONOLACTONE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 85045505107     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-53.
2. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-8.
3. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
4. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46: 1693-701.
5. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
6. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
7. Andreou I, Tousoulis D, Tentolouris C, Antoniades C, Stefanadis C. Potential role of endothelial progenitor cells in the pathophysiology of heart failure: clinical implications and perspectives. Atherosclerosis 2006; 189: 247-54.
8. Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006; 114: 2604-10.
9. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-7.
10. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
11. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
12. Marumo T, Uchimura H, Hayashi M, Hishikawa K, Fujita T. Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 2006; 48: 490-6.
13. Thum T, Schmitter K, Fleissner F, et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2011; 32: 1275-86.
14. Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119: 70 e23-30.
15. Chen JZ, Zhu JH, Wang XX, et al. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 2004; 36: 233-9.
16. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
17. Kissel CK, Lehmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007; 49: 2341-9.
18. Valgimigli M, Rigolin GM, Fucili A, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004; 110: 1209-12.
19. Nonaka-Sarukawa M, Yamamoto K, Aoki H, et al. Circulating endothelial progenitor cells in congestive heart failure. Int J Cardiol 2007; 119: 344-8.
20. Lev EI, Leshem-Lev D, Mager A, et al. Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. Eur Heart J 2010; 31: 2625-32.
21. Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis 2011; 214: 151-7.
22. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002; 39: 351-8.
23. Jung C, Florvaag A, Oberle V, et al. Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst 2012; 13: 401-6.
24. Ladage D, Schutzeberg N, Dartsch T, et al. Hyperaldosteronism is associated with a decrease in number and altered growth factor expression of endothelial progenitor cells in rats. Int J Cardiol 2011; 149: 152-6.
25. Alba AC, Lalonde SD, Rao V, Walter S, Guyatt GH, Ross HJ. Circulating proangiogenic progenitor cells independently predict functional capacity in heart failure patients. Can J Cardiol 2013; 29: 664-71.